Literature DB >> 21321135

Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity.

Ranjith Rajendran1, Eilidh Mowat, Elaine McCulloch, David F Lappin, Brian Jones, Sue Lang, Jayesh B Majithiya, Peter Warn, Craig Williams, Gordon Ramage.   

Abstract

This study investigated the phase-dependent expression and activity of efflux pumps in Aspergillus fumigatus treated with voriconazole. Fourteen strains were shown to become increasingly resistant in the 12-h (16- to 128-fold) and 24-h (>512-fold) phases compared to 8-h germlings. An Ala-Nap uptake assay demonstrated a significant increase in efflux pump activity in the 12-h and 24-h phases (P<0.0001). The efflux pump activity of the 8-h germling cells was also significantly induced by voriconazole (P<0.001) after 24 h of treatment. Inhibition of efflux pump activity with the competitive substrate MC-207,110 reduced the voriconazole MIC values for the A. fumigatus germling cells by 2- to 8-fold. Quantitative expression analysis of AfuMDR4 mRNA transcripts showed a phase-dependent increase as the mycelial complexity increased, which was coincidental with a strain-dependent increase in azole resistance. Voriconazole also significantly induced this in a time-dependent manner (P<0.001). Finally, an in vivo mouse biofilm model was used to evaluate efflux pump expression, and it was shown that AfuMDR4 was constitutively expressed and significantly induced by treatment with voriconazole after 24 h (P<0.01). Our results demonstrate that efflux pumps are expressed in complex A. fumigatus biofilm populations and that this contributes to azole resistance. Moreover, voriconazole treatment induces efflux pump expression. Collectively, these data may provide evidence for azole treatment failures in clinical cases of aspergillosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21321135      PMCID: PMC3088214          DOI: 10.1128/AAC.01189-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  In vivo biofilm composition of Aspergillus fumigatus.

Authors:  Céline Loussert; Christine Schmitt; Marie-Christine Prevost; Viviane Balloy; Elie Fadel; Bruno Philippe; Catherine Kauffmann-Lacroix; Jean Paul Latgé; Anne Beauvais
Journal:  Cell Microbiol       Date:  2009-11-04       Impact factor: 3.715

Review 2.  Regulation of multidrug resistance in pathogenic fungi.

Authors:  Joachim Morschhäuser
Journal:  Fungal Genet Biol       Date:  2009-08-07       Impact factor: 3.495

3.  Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms.

Authors:  Eilidh Mowat; Sue Lang; Craig Williams; Elaine McCulloch; Brian Jones; Gordon Ramage
Journal:  J Antimicrob Chemother       Date:  2008-09-26       Impact factor: 5.790

4.  Anti-Candida-biofilm activity of micafungin is attenuated by voriconazole but restored by pharmacological inhibition of Hsp90-related stress responses.

Authors:  Yukihiro Kaneko; Hideaki Ohno; Hidesuke Fukazawa; Yuko Murakami; Yoshifumi Imamura; Shigeru Kohno; Yoshitsugu Miyazaki
Journal:  Med Mycol       Date:  2010-06       Impact factor: 4.076

5.  The effects of antifungal agents to conidial and hyphal forms of Aspergillus fumigatus.

Authors:  Wendy W J van de Sande; Mehri Tavakol; Wim van Vianen; Irma A J M Bakker-Woudenberg
Journal:  Med Mycol       Date:  2010-02       Impact factor: 4.076

6.  Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.

Authors:  I I Raad; H A Hanna; M Boktour; Y Jiang; H A Torres; C Afif; D P Kontoyiannis; R Y Hachem
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528

Review 7.  Efflux-mediated antifungal drug resistance.

Authors:  Richard D Cannon; Erwin Lamping; Ann R Holmes; Kyoko Niimi; Philippe V Baret; Mikhail V Keniya; Koichi Tanabe; Masakazu Niimi; Andre Goffeau; Brian C Monk
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

Review 8.  The characteristics of Aspergillus fumigatus mycetoma development: is this a biofilm?

Authors:  Eilidh Mowat; Craig Williams; Brian Jones; Susan McChlery; Gordon Ramage
Journal:  Med Mycol       Date:  2008-07-24       Impact factor: 4.076

9.  Time course global gene expression analysis of an in vivo Candida biofilm.

Authors:  Jeniel E Nett; Alexander J Lepak; Karen Marchillo; David R Andes
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

10.  Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.

Authors:  Susan J Howard; Dasa Cerar; Michael J Anderson; Ahmed Albarrag; Matthew C Fisher; Alessandro C Pasqualotto; Michel Laverdiere; Maiken C Arendrup; David S Perlin; David W Denning
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

View more
  47 in total

1.  Azole antifungal resistance today: focus on Aspergillus.

Authors:  Paul Bowyer; Caroline B Moore; Riina Rautemaa; David W Denning; Malcolm D Richardson
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

2.  A Combination Fluorescence Assay Demonstrates Increased Efflux Pump Activity as a Resistance Mechanism in Azole-Resistant Vaginal Candida albicans Isolates.

Authors:  Somanon Bhattacharya; Jack D Sobel; Theodore C White
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

3.  Microbial glycoside hydrolases as antibiofilm agents with cross-kingdom activity.

Authors:  Brendan D Snarr; Perrin Baker; Natalie C Bamford; Yukiko Sato; Hong Liu; Mélanie Lehoux; Fabrice N Gravelat; Hanna Ostapska; Shane R Baistrocchi; Robert P Cerone; Elan E Filler; Matthew R Parsek; Scott G Filler; P Lynne Howell; Donald C Sheppard
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-20       Impact factor: 11.205

4.  Aspergillus fumigatus Afssn3-Afssn8 Pair Reverse Regulates Azole Resistance by Conferring Extracellular Polysaccharide, Sphingolipid Pathway Intermediates, and Efflux Pumps to Biofilm.

Authors:  Nanbiao Long; Liping Zeng; Guowei Zhong; Shanlei Qiao; Lei Li
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

5.  Global transcriptome changes underlying colony growth in the opportunistic human pathogen Aspergillus fumigatus.

Authors:  John G Gibbons; Anne Beauvais; Remi Beau; Kriston L McGary; Jean-Paul Latgé; Antonis Rokas
Journal:  Eukaryot Cell       Date:  2011-07-01

Review 6.  Biofilms 2012: new discoveries and significant wrinkles in a dynamic field.

Authors:  Susanne Haussler; Clay Fuqua
Journal:  J Bacteriol       Date:  2013-04-26       Impact factor: 3.490

7.  Azole drug import into the pathogenic fungus Aspergillus fumigatus.

Authors:  Brooke D Esquivel; Adam R Smith; Martin Zavrel; Theodore C White
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

8.  Aspergillus fumigatus DBM 4057 biofilm formation is inhibited by chitosan, in contrast to baicalein and rhamnolipid.

Authors:  Eva Kvasničková; Vít Paulíček; Martina Paldrychová; Richard Ježdík; Olga Maťátková; Jan Masák
Journal:  World J Microbiol Biotechnol       Date:  2016-09-22       Impact factor: 3.312

9.  DL-2-hydroxyisocaproic acid attenuates inflammatory responses in a murine Candida albicans biofilm model.

Authors:  M T Nieminen; M Hernandez; L Novak-Frazer; H Kuula; G Ramage; P Bowyer; P Warn; T Sorsa; R Rautemaa
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

10.  Extracellular DNA release acts as an antifungal resistance mechanism in mature Aspergillus fumigatus biofilms.

Authors:  Ranjith Rajendran; Craig Williams; David F Lappin; Owain Millington; Margarida Martins; Gordon Ramage
Journal:  Eukaryot Cell       Date:  2013-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.